WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has announced the groundbreaking of its new R&D and manufacturing site in Singapore.
This milestone, following the announcement of the new site in 2022, marks another step forward in WuXi AppTec’s mission to continuously enhance its CRDMO enabling platform to better support customers worldwide in advancing healthcare treatments and innovations.
The new 50-acre Singapore site is located in the thriving Tuas Biomedical Park with the master planning and development by JTC to encompass a total of seven plants at its full capacity, providing active pharmaceutical ingredient (API) R&D and manufacturing services for small molecules, oligonucleotides, peptides, and complex synthetic conjugates.
Embracing industry-leading green chemistry technology initiatives, this new site is dedicated to improving industrial practices and promoting sustainable development of the local community. As a key part of the company’s global network, the Singapore site will integrate closely with WuXi AppTec’s existing sites across Asia, Europe, and North America, offering effective CRDMO solutions for new drug R&D from discovery to commercialisation with expanded flexibility and scalability.
The new Singapore site is projected to start operation in 2027 and will be built in different phases. The site is expected to bring approximately 1,600 employment opportunities once fully built.
